评估广泛性焦虑障碍患者临床试验中3种结局量表的信号检测特性

Q. Jiang, S. Ahmed, R. Pedersen, J. Musgnung, R. Entsuah
{"title":"评估广泛性焦虑障碍患者临床试验中3种结局量表的信号检测特性","authors":"Q. Jiang,&nbsp;S. Ahmed,&nbsp;R. Pedersen,&nbsp;J. Musgnung,&nbsp;R. Entsuah","doi":"10.1016/j.nurx.2006.05.024","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>This analysis assessed correlations between the signal detection properties (drug vs placebo) of 3 outcome scales—the 14-item Hamilton Rating Scale for Anxiety (HAM-A), the Clinician Global Impression of Severity (CGI-S), and the Clinical Global Impression of Improvement (CGI-I)—in generalized anxiety disorder (GAD) clinical trials.</p></div><div><h3>Methods</h3><p>Data from 5 randomized, double-blind, placebo-controlled venlafaxine XR studies in adult patients with GAD were pooled and examined individually. For all rating scales, Pearson correlation coefficients were calculated for all patients at each visit and by treatment arm. To evaluate signal detection properties, effect sizes and <em>P</em> values based on the pooled and individual study data were examined for the 3 scales.</p></div><div><h3>Results</h3><p>At pretreatment visits, for the HAM-A and CGI-S, respectively, 1837 and 1831 observations were available, with mean scores of 25.8 and 4.5, and the correlation coefficient between the 2 scales was 0.55 (<em>P</em> &lt; 0.0001). Correlation coefficients at week 1 were 0.69 (HAM-A/CGI-S), 0.66 (HAM-A/CGI-I), and 0.55 (CGI-S/CGI-I). Correlation coefficients increased each week, and at final visit were 0.83 (HAM-A/CGI-S), 0.84 (HAM-A/CGI-I), and 0.82 (CGI-I/CGI-S). All correlations were significant (<em>P</em> &lt; 0.0001) and were of comparable magnitude in the venlafaxine XR and placebo groups. Pooled effect sizes (venlafaxine XR <em>versus</em> placebo) were 0.37, 0.41, and 0.40 for HAM-A, CGI-S, and CGI-I, respectively (week 8 LOCF). Across studies, effect sizes ranged from 0.21 to 0.55, 0.23 to 0.68, and 0.26 to 0.59 for the HAM-A, CGI-S, and CGI-I, respectively. As with the pooled data, however, within studies, they were more consistent across the 3 outcome measures. All 3 outcome measures reached statistical significance (<em>P</em> &lt; 0.05) in 4 of 5 studies.</p></div><div><h3>Conclusions</h3><p>The 3 scales were consistently correlated in all studies, and the correlations increased during the conduct of the study. Effect sizes based on different scales in the same studies were more similar than effect sizes based on the same scale in different studies. Furthermore, no one scale stood out as having consistently better signal detection properties than the others.</p></div>","PeriodicalId":87195,"journal":{"name":"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics","volume":"3 3","pages":"Page 411"},"PeriodicalIF":0.0000,"publicationDate":"2006-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.nurx.2006.05.024","citationCount":"0","resultStr":"{\"title\":\"Assessing the Signal Detection Properties of 3 Outcome Scales Used in Clinical Trials of Patients with Generalized Anxiety Disorder\",\"authors\":\"Q. Jiang,&nbsp;S. Ahmed,&nbsp;R. Pedersen,&nbsp;J. Musgnung,&nbsp;R. Entsuah\",\"doi\":\"10.1016/j.nurx.2006.05.024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>This analysis assessed correlations between the signal detection properties (drug vs placebo) of 3 outcome scales—the 14-item Hamilton Rating Scale for Anxiety (HAM-A), the Clinician Global Impression of Severity (CGI-S), and the Clinical Global Impression of Improvement (CGI-I)—in generalized anxiety disorder (GAD) clinical trials.</p></div><div><h3>Methods</h3><p>Data from 5 randomized, double-blind, placebo-controlled venlafaxine XR studies in adult patients with GAD were pooled and examined individually. For all rating scales, Pearson correlation coefficients were calculated for all patients at each visit and by treatment arm. To evaluate signal detection properties, effect sizes and <em>P</em> values based on the pooled and individual study data were examined for the 3 scales.</p></div><div><h3>Results</h3><p>At pretreatment visits, for the HAM-A and CGI-S, respectively, 1837 and 1831 observations were available, with mean scores of 25.8 and 4.5, and the correlation coefficient between the 2 scales was 0.55 (<em>P</em> &lt; 0.0001). Correlation coefficients at week 1 were 0.69 (HAM-A/CGI-S), 0.66 (HAM-A/CGI-I), and 0.55 (CGI-S/CGI-I). Correlation coefficients increased each week, and at final visit were 0.83 (HAM-A/CGI-S), 0.84 (HAM-A/CGI-I), and 0.82 (CGI-I/CGI-S). All correlations were significant (<em>P</em> &lt; 0.0001) and were of comparable magnitude in the venlafaxine XR and placebo groups. Pooled effect sizes (venlafaxine XR <em>versus</em> placebo) were 0.37, 0.41, and 0.40 for HAM-A, CGI-S, and CGI-I, respectively (week 8 LOCF). Across studies, effect sizes ranged from 0.21 to 0.55, 0.23 to 0.68, and 0.26 to 0.59 for the HAM-A, CGI-S, and CGI-I, respectively. As with the pooled data, however, within studies, they were more consistent across the 3 outcome measures. All 3 outcome measures reached statistical significance (<em>P</em> &lt; 0.05) in 4 of 5 studies.</p></div><div><h3>Conclusions</h3><p>The 3 scales were consistently correlated in all studies, and the correlations increased during the conduct of the study. Effect sizes based on different scales in the same studies were more similar than effect sizes based on the same scale in different studies. Furthermore, no one scale stood out as having consistently better signal detection properties than the others.</p></div>\",\"PeriodicalId\":87195,\"journal\":{\"name\":\"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics\",\"volume\":\"3 3\",\"pages\":\"Page 411\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.nurx.2006.05.024\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1545534306000940\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1545534306000940","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本分析评估了广泛性焦虑障碍(GAD)临床试验中3个结果量表(14项汉密尔顿焦虑量表(HAM-A)、临床医生严重程度总体印象(CGI-S)和临床总体印象改善(CGI-I)的信号检测特性(药物与安慰剂)之间的相关性。方法对5项随机、双盲、安慰剂对照的文拉法辛XR研究中成人广泛性焦虑症患者的数据进行汇总和单独分析。对于所有的评分量表,Pearson相关系数在每次就诊时和按治疗组计算。为了评估信号检测特性,对3个量表进行了基于合并和单独研究数据的效应量和P值的检验。结果HAM-A和CGI-S的预处理次数分别为1837次和1831次,平均得分分别为25.8分和4.5分,两个量表的相关系数为0.55 (P <0.0001)。第1周的相关系数分别为0.69 (HAM-A/CGI-S)、0.66 (HAM-A/CGI-I)和0.55 (CGI-S/CGI-I)。相关系数每周增加,最终访视时分别为0.83 (HAM-A/CGI-S)、0.84 (HAM-A/CGI-I)和0.82 (CGI-I/CGI-S)。所有相关性均显著(P <0.0001),并且在文拉法辛XR组和安慰剂组中具有相当的程度。HAM-A、CGI-S和CGI-I的合并效应量(文拉法辛XR与安慰剂相比)分别为0.37、0.41和0.40(第8周LOCF)。在所有研究中,HAM-A、CGI-S和CGI-I的效应量分别为0.21至0.55、0.23至0.68和0.26至0.59。然而,与汇总数据一样,在研究中,它们在三个结果测量中更加一致。3个结局指标均达到统计学意义(P <0.05)。结论3种量表在所有研究中均具有一致的相关性,且在研究过程中相关性不断增强。同一研究中基于不同尺度的效应量比不同研究中基于相同尺度的效应量更相似。此外,没有一个刻度比其他刻度具有更好的信号检测特性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Assessing the Signal Detection Properties of 3 Outcome Scales Used in Clinical Trials of Patients with Generalized Anxiety Disorder

Introduction

This analysis assessed correlations between the signal detection properties (drug vs placebo) of 3 outcome scales—the 14-item Hamilton Rating Scale for Anxiety (HAM-A), the Clinician Global Impression of Severity (CGI-S), and the Clinical Global Impression of Improvement (CGI-I)—in generalized anxiety disorder (GAD) clinical trials.

Methods

Data from 5 randomized, double-blind, placebo-controlled venlafaxine XR studies in adult patients with GAD were pooled and examined individually. For all rating scales, Pearson correlation coefficients were calculated for all patients at each visit and by treatment arm. To evaluate signal detection properties, effect sizes and P values based on the pooled and individual study data were examined for the 3 scales.

Results

At pretreatment visits, for the HAM-A and CGI-S, respectively, 1837 and 1831 observations were available, with mean scores of 25.8 and 4.5, and the correlation coefficient between the 2 scales was 0.55 (P < 0.0001). Correlation coefficients at week 1 were 0.69 (HAM-A/CGI-S), 0.66 (HAM-A/CGI-I), and 0.55 (CGI-S/CGI-I). Correlation coefficients increased each week, and at final visit were 0.83 (HAM-A/CGI-S), 0.84 (HAM-A/CGI-I), and 0.82 (CGI-I/CGI-S). All correlations were significant (P < 0.0001) and were of comparable magnitude in the venlafaxine XR and placebo groups. Pooled effect sizes (venlafaxine XR versus placebo) were 0.37, 0.41, and 0.40 for HAM-A, CGI-S, and CGI-I, respectively (week 8 LOCF). Across studies, effect sizes ranged from 0.21 to 0.55, 0.23 to 0.68, and 0.26 to 0.59 for the HAM-A, CGI-S, and CGI-I, respectively. As with the pooled data, however, within studies, they were more consistent across the 3 outcome measures. All 3 outcome measures reached statistical significance (P < 0.05) in 4 of 5 studies.

Conclusions

The 3 scales were consistently correlated in all studies, and the correlations increased during the conduct of the study. Effect sizes based on different scales in the same studies were more similar than effect sizes based on the same scale in different studies. Furthermore, no one scale stood out as having consistently better signal detection properties than the others.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信